

Appl. No. : 08/484,594
Filed : June 7, 1995

D1
cancel

administering to a mammal afflicted with [a] demyelination [disorder] a pharmaceutically effective demyelination inhibiting amount of prosaposin or a neurotrophic fragment comprising amino acids 8-29 of SEQ ID NO: 3, or including the active neurotrophic fragment located within amino acids 8-29 of SEQ ID NO: 3.

D2

314. (Amended) The method of Claim 12, wherein said demyelination [disorder] is [selected from the group consisting of:] due to multiple sclerosis, [acute disseminated leukoencephalitis, progressive multifocal leukoencephalitis and adrenal leukodystrophy], ischemic injury or traumatic injury.

7 18. (Twice amended) A method for [preventing or slowing] inhibiting the progress of ~~neural~~ or myelin degeneration in neural tissue, comprising:

D3

contacting [neuronal] neural tissue susceptible to such degeneration with prosaposin or a neurotrophic fragment comprising amino acids 8-29 of SEQ ID NO: 3, or including the active neurotrophic fragment located within amino acids 8-29 of SEQ ID NO: 3.

D4

22. (Twice amended) A method for [of] treating neuronal degeneration in the central of peripheral nervous system, comprising the step of administering to a mammal suffering from [said] a neurodegenerative disease an amount of a prosaposin fragment effecting to [retard or halt] inhibit neuronal degeneration, wherein said fragment includes the active neurotrophic fragment located within amino acids 8-29 of SEQ ID NO: 3.

Claim 23, line 1, please replace "administration" with ~~--~~administering step--.